Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients

Transplant Infectious Disease

Volumn 13, Issue 2, 2011, Pages 145-153

  Iwasenko, J M ^a,b   Scott, G M ^a,b   Naing, Z ^a   Glanville, A R ^b,c   Rawlinson, W D ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antiviral resistance; Human cytomegalovirus; Transplantation

Indexed keywords

CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; PROTEIN KINASE; VALGANCICLOVIR; VIRUS ENZYME;

ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG SENSITIVITY; GENE MUTATION; GENETIC VARIABILITY; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; LUNG TRANSPLANTATION; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRAL GENETICS;

ANTIVIRAL AGENTS; AUSTRALIA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HEART TRANSPLANTATION; HUMANS; LUNG TRANSPLANTATION; MUTATION; VIRAL PROTEINS;

EID: 79953312642     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00584.x     Document Type: Article

References (33)

1. Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 2001; 54: 84-88.
2. Keven K, Basu A, Tan H, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004; 36 (10): 3107-3112.
3. Taber DJ, Ashcraft E, Baillie GM, et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004; 6 (3): 101-109.
4. Boeckh M, Nichols W. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008.
5. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006; 16: 281-287.
6. Snydman D. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 2006; 16: 289-295.
7. Freeman RB. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host. Expert Opin Pharmacother 2004; 5 (9): 2007-2016.
8. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007; 45 (4): 439-447.
9. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Richards NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001; 184 (12): 1598-1602.
10. Chou S. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis 1999; 1: 105-114.
11. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang M, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185 (1): 20-27.
12. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358 (6382): 160-162.
13. Sullivan V, Talarico CL, Stanat SC, David M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 358 (6382): 162-164.
14. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999; 12 (2): 286-297.
15. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188: 32-39.
16. Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 2005; 77 (3): 425-429.
17. De Clercq E. Antiviral drugs: current state of the art. J Clin Virol 2001; 22: 73-89.
18. Chou S, Van Wechel LC, Lichy HM, Marousek GI. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005; 49 (7): 2710-2715.
19. Scott GM, Isaacs MA, Zeng F, Kesson AM, Rawlinson WD. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J Med Virol 2004; 74 (1): 85-93.
20. Iwasenko JM, Scott GM, Ziegler JB, Rawlinson WD. Emergence of multiple antiviral resistant CMV strains in a highly immuncompromised patient. J Clin Virol 2007; 40 (2): 152-155.
21. Iwasenko JM, Scott GM, Rawlinson WD, Keogh A, Mitchell D, Chou S. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J Med Virol 2009; 81: 507-510.
22. Cihlar T, Fuller MD, Cherrington JM. Characterisation of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998; 72 (7): 5927-5936.
23. Iwasenko JM, Scott GM, Chou S, Rawlinson WD. Human cytomegalovirus antiviral resistance in immunocompromised transplant recipients. Abstract #630. Transplantation 2008; 86 (2S): 221.
24. Chou S, Lurain NS, Weinberg A, et al. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob Agents Chemother 1999; 43 (6): 1500-1502.
25. Ducancelle A, Gravisse J, Alain S, et al. Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet. J Virol Methods 2005; 125 (2): 145-151.
26. Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002; 185: 162-169.
27. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189 (9): 1615-1618.
28. Hebart H, Jahn G, Sinzger C, Kanz L, Einsele H. CMV infection in bone marrow and solid organ transplant patients in the era of antiviral prophylaxis. Herpes 2000; 7 (1): 13-17.
29. Jabs DA, Martin BK, Forman MS, et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol 2003; 135 (1): 26-34.
30. Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J Virol 2010; 84 (14): 7195-7203.
31. Bauer CC, Jaksch P, Aberle SW, et al. Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment. J Clin Microbiol 2007; 45 (2): 324-328.
32. Hamprecht K, Eckle T, Prix L, Faul C, Einsele H, Jahn G. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 2003; 187: 139-143.
33. Baillie GM. Pharmacokinetics of antiviral agents for the treatment of cytomegalovirus infection. Am J Health-System Pharm 2005; 62 (8, Suppl 1): S14-S17.